On the 31st of December, Westfield Capital Management added 3.1 million Ironwood Pharmaceuticals, Inc. (IRWD) shares for $36 million at an average price of $11.39 per share.
Shares of Ironwood Pharmaceuticals, Inc. are up 0.88% since the transaction.
Westfield Capital Management’s holding in Ironwood Pharmaceuticals, Inc. increased to about 8.5 million shares with the purchase.
Westfield Capital Management first bought Ironwood Pharmaceuticals, Inc. stock in the second quarter of 2018.
Westfield Capital Management also owns Bristol-Myers Squibb Co (NYSE:), Thermo Fisher Scientific Inc (NYSE:), Bio-Rad Laboratories Inc (NYSE:) and Blueprint Medicines Corp (NASDAQ:).
Ironwood Pharmaceuticals, Inc. is its number two position by number of shares and market value among biotechnology & life sciences stocks.
Other investors who also added to their Ironwood Pharmaceuticals, Inc. shares include California State Teachers Retirement System, Victory Capital Management, and Gotham Asset Management.
In contrast, Fisher Asset Management, Millennium Management, and the T. Rowe Price Equity Income Fund reduced IRWD shares, while Royce & Associates sold all their IRWD shares.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.